Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RXXYP
ADC Name
Patritumab-eribulin-D4
Synonyms
Patritumab-eribulin-D4
   Click to Show/Hide
Organization
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Drug Status
Investigative
Antibody Name
undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Combination Type
MC-GGFG-eribulin
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.03982
nM
CVCL_0179
Invasive breast carcinoma
Half Maximal Effective Concentration (EC50) 
0.04299
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.09942
nM
CVCL_0031
Invasive breast carcinoma
Half Maximal Effective Concentration (EC50) 
0.778
nM
CVCL_1255
Breast ductal carcinoma
Half Maximal Effective Concentration (EC50) 
1.413
nM
CVCL_0419
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
3.266
nM
CVCL_2077
Breast ductal carcinoma
Half Maximal Effective Concentration (EC50) 
13.86
nM
CVCL_1603
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.03982 nM High HER3 expression (HER3 +++)
Method Description
A Cell line test on BT474
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.04299 nM Moderate HER3 expression (HER3++)
Method Description
A Cell line test on SKBR3
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.09942 nM High HER3 expression (HER3 +++)
Method Description
A Cell line test on MCF-7
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.778 nM High HER3 expression (HER3 +++)
Method Description
A Cell line test on HCC1569
In Vitro Model Breast ductal carcinoma HCC1569 cells CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.413 nM Moderate HER3 expression (HER3++)
Method Description
A Cell line test on MDA-MB-468
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.266 nM Moderate HER3 expression (HER3++)
Method Description
A Cell line test on JIMT-1
In Vitro Model Breast ductal carcinoma JIMT-1 cells CVCL_2077
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 13.86 nM Moderate HER3 expression (HER3++)
Method Description
A Cell line test on NCI-N87
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Anti-HER3 antibody drug conjugate, composition thereof, and use thereof